Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Nicole Ona

Nurse Practitioner, Acute Care Houston, TX Nurse Practitioner

NPI 1588299861 CMS profile 11011611

6609 W Sam Houston Pkwy S Ste 102, Houston, TX 77072

Open in the dashboard

General payments

$11,834

449 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nicole Ona of Houston, TX is reported in the CMS Open Payments database as having received $11,834 across 449 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,587 70
2024 General $1,691 73
2023 General $2,448 91
2022 General $3,982 116
2021 General $2,125 99

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicole Ona
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Nicole Ona were reported at $1,587. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Nicole Ona Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $2,125 $123 $38–$327 $132
2022 $3,982 $130 $44–$369 $149
2023 $2,448 $144 $49–$410 $160
2024 $1,691 $146 $48–$433 $164
2025 $1,587 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abiomed $1,661 18 payments
  2. AstraZeneca Pharmaceuticals LP $1,204 54 payments
  3. Medtronic, Inc. $1,183 21 payments
  4. Janssen Pharmaceuticals, Inc $1,070 51 payments
  5. Novartis Pharmaceuticals Corporation $921 48 payments
  6. Amgen Inc. $814 45 payments
  7. Merck Sharp & Dohme Corporation $802 44 payments
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $675 32 payments
  9. Impulse Dynamics (USA) Inc. $657 7 payments
  10. E.R. Squibb & Sons, L.L.C. $355 10 payments
  11. Other $2,490 119 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,282 444 payments
  2. Travel and Lodging $553 5 payments
Products named General payments · program years 2021–2025
  1. Impella $1,474 15 payments
  2. XARELTO $1,070 51 payments
  3. FARXIGA $1,034 42 payments
  4. VENASEAL $995 14 payments
  5. VERQUVO $891 48 payments
  6. Repatha $698 38 payments
  7. LifeVest $675 32 payments
  8. LEQVIO $652 34 payments
  9. Optimizer $632 6 payments
  10. Ozempic $255 9 payments
  11. Other $4,160 194 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

449 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Acute Care in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record